To improve T cell recruitment into the tumor, CAR-T cells were also engineered to target antigens such as integrins, which are selectively enriched in the TME, or vascular endothelial growth factor (VEGF) receptor-2 (VEGFR2), a highly expressed antigen enriched in the tumor vasculature. Here, KDR is linked to neoplasm.